Akums Drugs IPO Allotment Status – Akums Drugs & Pharma’s first public offering (IPO) took place from July 30 to August 1st. The business priced its shares between Rs 646 to Rs 679 per share, with a lot size of 22 shares. On Friday, August 02, Akums Drugs and Pharmaceuticals is expected to complete the foundation for sharing its shares.
Over the weekend, or at the latest by Monday, August 5, bidders will receive notifications, alerts, or emails regarding the debiting of their funds or the revocation of their IPO mandate. The investor response to the pharma player’s IPO was respectable.
Akums Drugs IPO Details (Price, Date, GMP)
| Open Date | 30 Jul 2024 |
| Close Date | 01 Aug 2024 |
| IPO Price Range | ₹ 646 to ₹ 679 |
| Listing Exchange | BSE NSE |
| IPO Size | ₹ 1856.74 Cr |
| Listing Date | 06 Aug 2024 |
| Lot Size | 22 Shares |
| Latest IPO Details | Check Here |
How to Check IPO allotment status?
Investors can use the BSE website or the IPO registrar’s portal, Link Intime India Private Ltd., to view their IPO allotment status online.
- Go to Link Intime India Private Ltd.’s IPO registration website.
- From the dropdown menu, choose ‘Akums Drugs & Pharmaceuticals Limited’.
- Select the PAN, application number, DP/Client ID, or account number/IFSC that corresponds to your identification.
- Enter the necessary information.
- To view the allotment status, click “Submit.”
Read Also – Bulkcorp IPO Date, Price, GMP, and Expert Review
About Akums Drugs
Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (also known as a “CDMO”) that was established in April 2004 and provides a wide range of pharmaceutical goods and services both domestically in India and internationally. The company’s primary business is centered on offering its clients end-to-end product development and manufacturing solutions, and it owns the intellectual property of the production methods for several of its formulations.
The company produces a broad variety of dosage forms, such as gummy bears, dry powder injections, topical preparations, eye drops, vials, ampoules, tablets, capsules, and liquid orals. The company created formulations for 26 of the top 30 pharmaceutical companies in India during the 2024 fiscal year. Furthermore, it is anticipated that the new injectable facilities would be operational by the 2025 fiscal year.
